← All trials
NCT06005558
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2023
- Primary completion
- Jan 30, 2024
- Completion date
- Feb 15, 2024
- First posted
- Aug 22, 2023
- Last posted
- Aug 22, 2023
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute, EgyptLead sponsor
- National Cancer Institute (NCI)Overall official - principal investigator
- National Cancer Institute, EgyptReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.